COST PER RESPONDER OF BIMEKIZUMAB AGAINST IL17A, IL-12/23 AND IL-23 INHIBITORS IN THE TREATMENT OF PSORIATIC ARTHRITIS IN SWEDEN

被引：0
|
作者：
Lyris, N. [1 ]
Geale, K. [2 ,3 ]
Aldven, M. [3 ]
Engstrom, A. [4 ]
Willems, D. [5 ]
机构：
[1] UCB Pharma, Slough, Berks, England
[2] Umea Univ, Dept Publ Hlth & Clin Med, Dermatol & Venerol, Umea, Sweden
[3] Quantify Res, Stockholm, Sweden
[4] UCB Pharm, Stockholm, Sweden
[5] UCB Pharm, Brussels, Belgium
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE649
引用
收藏
页码：S178 / S178
页数：1
相关论文
共 50 条
  • [21] Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study
    Tiago Torres
    Luis Puig
    Ron Vender
    Charles Lynde
    Stefano Piaserico
    Jose M. Carrascosa
    Paolo Gisondi
    Esteban Daudén
    Curdin Conrad
    Pedro Mendes-Bastos
    Paulo Ferreira
    Luiz Leite
    Justin D. Lu
    J. Valerio
    M. Bruni
    F. Messina
    A. Nidegger
    M. Llamas-Velasco
    E. del Alcazar
    A. Mufti
    Kyra White
    G. Caldarola
    Laetitia Teixeira
    Paolo Romanelli
    K. Desai
    Spyridon Gkalpakiotis
    Marco Romanelli
    Jensen Yeung
    Miguel Nogueira
    Andrea Chiricozzi
    American Journal of Clinical Dermatology, 2021, 22 : 567 - 579
  • [22] Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease
    Ahmed Almradi
    Jurij Hanzel
    Rocio Sedano
    Claire E. Parker
    Brian G. Feagan
    Christopher Ma
    Vipul Jairath
    BioDrugs, 2020, 34 : 713 - 721
  • [23] Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease
    Almradi, Ahmed
    Hanzel, Jurij
    Sedano, Rocio
    Parker, Claire E.
    Feagan, Brian G.
    Ma, Christopher
    Jairath, Vipul
    BIODRUGS, 2020, 34 (06) : 713 - 721
  • [24] The IL-17/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis
    Vecellio, Matteo
    Hake, Vivien Xanath
    Davidson, Connor
    Carena, Maria Cristina
    Wordsworth, B. Paul
    Selmi, Carlo
    FRONTIERS IN IMMUNOLOGY, 2021, 11
  • [25] Combination Therapy With Tofacitinib and IL-17A or IL-23 Inhibition for the Treatment of Refractory Psoriatic Arthritis
    Yip, Ashley
    Chan, Jonathan
    Dutz, Jan
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1166 - 1166
  • [26] Systematic review: IL-12/23 or IL-23 antagonists and RTIs or ILD
    Reactions Weekly, 2020, 1819 (1) : 11 - 11
  • [27] IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors
    Nerviani, Alessandra
    Boutet, Marie-Astrid
    Tan, Wang Sin Gina
    Goldmann, Katriona
    Purkayastha, Nirupam
    Lajtos, Tamas Ajtos
    Hands, Rebecca
    Lewis, Myles
    Kelly, Stephen
    Pitzalis, Costantino
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (05) : 591 - 597
  • [28] IL-23 Skin and Joint Profiling in Psoriatic Arthritis: Novel Perspectives in Understanding Clinical Responses to IL-23 Inhibitors
    Nerviani, Alessandra
    Boutet, Marie-Astrid
    Tan, Wang Sin Gina
    Goldmann, Katriona
    Purkayastha, Nirupam
    Lajtos, Tamas
    Hands, Rebecca
    Lewis, Myles
    Kelly, Stephen
    Pitzalis, Costantino
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [29] Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study
    Borg, Emma
    Thoning, Henrik
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2021, 22 (06) : 901 - 902
  • [30] IL-23, not IL-12, Directs Autoimmunity to the Goodpasture Antigen
    Ooi, Joshua D.
    Phoon, Richard K. S.
    Holdsworth, Stephen R.
    Kitching, A. Richard
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (05): : 980 - 989
12345